{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:00:35Z","timestamp":1789984835186,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T00:00:00Z","timestamp":1387843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1038\/bjc.2013.798","type":"journal-article","created":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T09:17:27Z","timestamp":1387876647000},"page":"888-893","source":"Crossref","is-referenced-by-count":22,"title":["Pazopanib exposure decreases as a result of an ifosfamide-dependent drug\u2013drug interaction: results of a phase I study"],"prefix":"10.1038","volume":"110","author":[{"given":"P","family":"Hamberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W T A","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A B","family":"Suttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F A L M","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M L","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,24]]},"reference":[{"key":"BFbjc2013798_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00685732","volume":"36","author":"AV Boddy","year":"1995","unstructured":"Boddy AV, Cole M, Pearson AD, Idle JR (1995) The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 36: 53\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2013798_CR2","first-page":"5110","volume":"52","author":"Y Boucher","year":"1992","unstructured":"Boucher Y, Jain RK (1992) Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52: 5110\u20135114.","journal-title":"Cancer Res"},{"key":"BFbjc2013798_CR3","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/1535-7163.MCT-11-0997","volume":"11","author":"HA Burris 3rd","year":"2012","unstructured":"Burris HA 3rd, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR (2012) Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther 11: 1820\u20131828.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2013798_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/bjc.2011.608","volume":"106","author":"A Du Bois","year":"2012","unstructured":"Du Bois A, Vergote I, Wimberger P, Ray-Coquard I, Harter P, Curtis LB, Mitrica I (2012) Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I\/II trial of the AGO study group. Br J Cancer 106: 629\u2013632.","journal-title":"Br J Cancer"},{"key":"BFbjc2013798_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247.","journal-title":"Eur J Cancer"},{"key":"BFbjc2013798_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/clpt.2010.158","volume":"88","author":"BC Goh","year":"2010","unstructured":"Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88: 652\u2013659.","journal-title":"Clin Pharmacol Ther"},{"key":"BFbjc2013798_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","volume":"15","author":"P Hamberg","year":"2010","unstructured":"Hamberg P, Verweij J, Sleijfer S (2010a) (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. The Oncologist 15: 539\u2013547.","journal-title":"The Oncologist"},{"key":"BFbjc2013798_CR8","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1016\/j.ejca.2010.07.002","volume":"46","author":"P Hamberg","year":"2010","unstructured":"Hamberg P, Ratain MJ, Lesaffre E, Verweij J (2010b) Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 46: 2870\u20132878.","journal-title":"Eur J Cancer"},{"key":"BFbjc2013798_CR9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.bjc.6605696","volume":"102","author":"P Hamberg","year":"2010","unstructured":"Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S (2010c) Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Br J Cancer 102: 1699\u20131706.","journal-title":"Br J Cancer"},{"key":"BFbjc2013798_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure \u2013 an obstacle in cancer therapy. Nat Rev Cancer 4: 806\u2013813.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2013798_CR11","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15: 4220\u20134227.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013798_CR12","first-page":"967","volume":"29","author":"T Kerbusch","year":"2001","unstructured":"Kerbusch T, Mathot RAA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH (2001) Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 29: 967\u2013975.","journal-title":"Drug Metab Dispos"},{"key":"BFbjc2013798_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1538-7836.2012.04681.x","volume":"10","author":"J Kraan","year":"2012","unstructured":"Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, Verhoef C (2012) A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 10: 931\u2013939.","journal-title":"J Thromb Haemost"},{"key":"BFbjc2013798_CR14","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","volume":"25","author":"P Lorigan","year":"2007","unstructured":"Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study (2007) Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group study. J Clin Oncol 25: 3144\u20133150.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013798_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00280-012-1982-z","volume":"71","author":"R Plummer","year":"2013","unstructured":"Plummer R, Madi A, Effels M, Richly H, Nokay B, Rubin S, Ball HA, Weller S, Botbyl J, Gibson DM, Scheulen ME (2013) A phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 71: 93\u2013101.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2013798_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/bjc.2012.328","volume":"107","author":"S Sleijfer","year":"2012","unstructured":"Sleijfer S, Gorlia T, Lamers C, Burger H, Blay JY, Le Cesne A, Scurr M, Collin F, Pandite L, Marreaud S, Hohenberger P (2012) Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft tissue sarcoma: an EORTC-STBSG study. Br J Cancer 107: 639\u2013645.","journal-title":"Br J Cancer"},{"key":"BFbjc2013798_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, Mc Cann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061\u20131068.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013798_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1634\/theoncologist.2010-0095","volume":"15","author":"AR Tan","year":"2010","unstructured":"Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ, Burris HA 3rd (2010) Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 15: 1253\u20131261.","journal-title":"Oncologist"},{"key":"BFbjc2013798_CR19","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT Van der Graaf","year":"2012","unstructured":"Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Sch\u00f6ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double blind, placebo-controlled phase 3 trial. Lancet 379: 1879\u20131886.","journal-title":"Lancet"},{"key":"BFbjc2013798_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, KAalva SP, Kozin SV, Mino M, Cohen KS, Scaddden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhi AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145\u2013147.","journal-title":"Nat Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2013798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013798","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:21:04Z","timestamp":1684416064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,24]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["BFbjc2013798"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.798","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,24]]}}}